Cargando…
Discovery of Compound A – a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity
Glucocorticoids are among the most effective anti-inflammatory drugs, and are widely used for cancer therapy. Unfortunately, chronic treatment with glucocorticoids results in multiple side effects. Thus, there was an intensive search for selective glucocorticoid receptor (GR) activators (SEGRA), whi...
Autores principales: | Lesovaya, Ekaterina, Yemelyanov, Alexander, Swart, Amanda C., Swart, Pieter, Haegeman, Guy, Budunova, Irina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741564/ https://www.ncbi.nlm.nih.gov/pubmed/26436695 |
Ejemplares similares
-
Selective Activator of the Glucocorticoid Receptor Compound A Dissociates Therapeutic and Atrophogenic Effects of Glucocorticoid Receptor Signaling in Skin
por: Klopot, Anna, et al.
Publicado: (2015) -
Anti-Proliferative Effects of Compound A and Its Effect in Combination with Cisplatin in Cholangiocarcinoma Cells
por: Junking, Mutita, et al.
Publicado: (2020) -
The long winding road to the safer glucocorticoid receptor (GR) targeting therapies
por: Lesovaya, Ekaterina A., et al.
Publicado: (2022) -
Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy
por: Baida, Gleb, et al.
Publicado: (2018) -
REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids
por: Baida, Gleb, et al.
Publicado: (2015)